在复发性缺血性中风的设置中升高的第八因子
Nika Bakshi1, Maya S Kardouh1, Claire Wang1
1Internal Medicine, Oakland University William Beaumont School of Medicine, Royal Oak, USA.
Cureus
|December 24, 2025
概括
一名患者经历了多次中风,包括缺口性心脏病发作和基底动脉狭窄症,并用基塑剂和支架治疗. 随后,尽管使用了专利性支架,但却发生了关节梗塞,这导致发现了高水平的VIII因子水平,这表明了高凝血状态.
科学领域:
- 神经学 神经学
- 血管医学 血管医学
- 血液学 血液学 血液学
背景情况:
- 经常性缺血性中风可能由于各种因素而发生,包括动脉狭窄和高凝血状态.
- 后循环中的血栓事件,如基底动脉狭窄症,带来了重大的临床挑战.
- 识别潜在的高凝血性疾病对于管理复发性脑血管事件至关重要.
研究的目的:
- 在患有基底动脉狭窄和随后的关节梗塞的患者中呈现复发性缺血性中风的情况.
- 调查尽管内血管治疗成功,但复发性心脏病发作的潜在原因.
- 为了突出高凝血性工作在密码性中风复发中的诊断产量.
主要方法:
- 病例报告详细介绍了一名患有多次缺血性中风的52岁女性的临床表现,诊断工作和治疗.
- 对神经成像发现的审查,包括急性心脏病发作的MRI和血管评估的MRA/CTA.
- 实验室检查,包括高凝血检查.
主要成果:
- 患者经历了一次初始的缺口性心脏病发作,随后是中枢动脉静脉狭窄的中继性中风,该病患接受了用tenecteplase和支架治疗.
- 随后发生了一次庞丁性心脏病发作,尽管有一个专利的基底动脉支架.
- 过高凝血检查显示了因子VIII水平的升高.
结论:
- 升高的VIII因子水平可能会导致复发性缺血性中风,即使在成功治疗动脉狭窄后也是如此.
- 在复发性中风的情况下,全面的高凝血检查是必不可少的,特别是当传统的风险因素或治疗不能完全解释这些事件时.
- 这一案例强调了在密码性和复发性脑血管事件的病因学中考虑血栓性的重要性.
相关概念视频
Venous Thrombosis III: Interprofessional Care
257
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
257
Anticoagulant Drugs: Low-Molecular-Weight Heparins
1.6K
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
1.6K
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
2.0K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
2.0K
Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies
266
The key difference between Superficial Vein Thrombosis (SVT) and Deep Vein Thrombosis (DVT) lies in their location and severity.Clinical ManifestationsSVT typically presents with localized pain, tenderness, and redness along the course of a superficial vein, often accompanied by a palpable, cord-like structure under the skin. This condition is usually less dangerous than DVT but can be uncomfortable and may lead to complications such as cellulitis or, rarely, a clot extension into the deep...
266
Disorders of Hemostasis
1.9K
Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
1.9K
Extrinsic and Intrinsic Pathways of Hemostasis
11.8K
Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
11.8K


